Abbott Laboratories
NYSE:ABT
Intrinsic Value
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. [ Read More ]
The intrinsic value of one ABT stock under the Base Case scenario is 97.64 USD. Compared to the current market price of 107.53 USD, Abbott Laboratories is Overvalued by 9%.
Valuation Backtest
Abbott Laboratories
Run backtest to discover the historical profit from buying and selling ABT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Abbott Laboratories
Current Assets | 22.7B |
Cash & Short-Term Investments | 7.3B |
Receivables | 6.6B |
Other Current Assets | 8.8B |
Non-Current Assets | 50.5B |
Long-Term Investments | 799m |
PP&E | 10.2B |
Intangibles | 32.5B |
Other Non-Current Assets | 7.1B |
Current Liabilities | 13.8B |
Accounts Payable | 4.3B |
Accrued Liabilities | 7B |
Other Current Liabilities | 2.5B |
Non-Current Liabilities | 20.8B |
Long-Term Debt | 13.6B |
Other Non-Current Liabilities | 7.2B |
Earnings Waterfall
Abbott Laboratories
Revenue
|
40.3B
USD
|
Cost of Revenue
|
-18.1B
USD
|
Gross Profit
|
22.3B
USD
|
Operating Expenses
|
-15.6B
USD
|
Operating Income
|
6.6B
USD
|
Other Expenses
|
-1B
USD
|
Net Income
|
5.6B
USD
|
Free Cash Flow Analysis
Abbott Laboratories
ABT Profitability Score
Profitability Due Diligence
Abbott Laboratories's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Abbott Laboratories's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
ABT Solvency Score
Solvency Due Diligence
Abbott Laboratories's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Abbott Laboratories's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABT Price Targets Summary
Abbott Laboratories
According to Wall Street analysts, the average 1-year price target for ABT is 129.28 USD with a low forecast of 108.07 USD and a high forecast of 148.05 USD.
Ownership
ABT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ABT Price
Abbott Laboratories
Average Annual Return | 12.24% |
Standard Deviation of Annual Returns | 22.78% |
Max Drawdown | -35% |
Market Capitalization | 186.5B USD |
Shares Outstanding | 1 735 180 032 |
Percentage of Shares Shorted | 0.84% |
ABT News
Last Important Events
Abbott Laboratories
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Abbott Laboratories
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The company is headquartered in Abbott Park, Illinois and currently employs 113,000 full-time employees. The firm operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
Contact
IPO
Employees
Officers
The intrinsic value of one ABT stock under the Base Case scenario is 97.64 USD.
Compared to the current market price of 107.53 USD, Abbott Laboratories is Overvalued by 9%.